Abeer Mohamed Radi

lecturer of pharmacology- Faculty of veterinary medicine- Beni-suef university

Basic Informations

C.V

 

CURRICULUM VITAE

 

 

    Personal details

 

Name: Abeer Mohammed Radi

Nationality: Egyptian

Date of birth: 28-1-1975

Material status: Married

Address: Pharmacology Dept. Fac. Vet. Med. Beni-Suef University

 

Telephone:

                

                 Mobile 01155128282

                 Work 0822327982 (Tel/Fax)

E-Mail:, rouqaa2007@yahoo.com abeer.radi@vet.bsu.edu.eg

 

    Educational background

 

Date       Qualification and Institution

 

1997     Bachelor degree in Veterinary Medicine

               (Faculty of Veterinary Medicine, Cairo University, Beni-Suef )       

2002      Master degree in Vet. Pharmacology

               (Faculty of Veterinary Medicine, Cairo University, Beni-Suef )         

2008      Ph.D. thesis Vet. Pharmacology

               (Faculty of Veterinary Medicine, Cairo University, Beni-Suef )                

 

    Career History

 

Date            Job and Institution

 

1998-2002  Demonstrator of Pharmacology

                 (Faculty of Veterinary Medicine, Cairo University, Beni-Suef )

2002-2008 Assistant lecturer of Pharmacology

                 (Faculty of Veterinary Medicine, Cairo University, Beni-Suef )

2008 to date Lecturer of Pharmacology

                 (Faculty of Veterinary Medicine, Cairo University, Beni-Suef )

 

RESEARCH

Current research is on pharmacodynamics and pharmacokinetics of drugs and plants.

TEACHING / INSTRUCTION

Pharmacology (Pharmacodynamics and Pharmacokinetics of drugs)

 

Publications: 

1-Zaghloul, H.A.H., El-Gendy, A.A.M., Tohamy, M.A. and Radi, A.M. (2007): Effect of sulphadoxine-trimethoprim combination on some pharmacokinetic aspects of sulphadoxine in goats. BS. VET. MED. J., 17(1): 78-85.

2-Tohamy, M.A. and Radi, A.M. (2008): Bioavailability and pharmacokinetics of florfenicol in healthy foals. J. Egypt. Soc. Pharmacol. Exp. Ther., 29(2): 539-551.

3-A.A.M. El-Gendy, M.A. Tohamy and Abeer M. Radi (2009): Pharmacokinetic profile and some pharmacodynamic aspects of cefquinome in chickens. BS. VET. MED. J., 19(2): 33-37.

 

4-Radwan.A.I and Abeer, M.Radi ( 2010):Antimicrobial  activity of some cephalosporins with special reference to their effects on body weight and immune response to new castle disease vaccine in fayoumy chiks . beni-suief veterinary medical journal 6th sci-conf. vol.20,No1,p.236-242.

 

 5-A.A.M. El-Gendy, M.A. Tohamy and Abeer M. Radi (2011):  Some pharmacological studies of cephradine in broilers. BS. VET. MED. J.,.

 

6-Ghada, M. Safwat and Abeer, M. Radi (2011): Evaluation of the antioxidant protective effect of oxytocin and silymarin against gentamycin- induced nephrotoxcicity in rat. BS. VET. MED. J. vol(21),No.1:1-7.

7- Abeer.M.Radi (2012): pharmacokinetics and bioavailability of spectinomycin in sheep., Suez canal Veterinary medicine journal(SCVMJ, XVII(2):161-169.

8-  F.I. Abo El-Elaa, A.M. Radia*, H.A. El-Bannab, A.A.M. El-Gendya & M.A. Tohamy (2014):Pharmacokinetics of di?oxacin in healthy and E. coli-infected broiler chickens.  British poultry science journal, Volume 55Issue 6, pages 830-836.

9- Radwan, I.A., Abed, A.H., Abeer, M.Radi, Ibrahim, M.,A., Abdallah, A.S.(2014): Effect of Thyme, Clove and Cinnamon Essential Oils on Candida Albicans and Moulds Isolated From Different Sources.  American journal of animal and veterinary science, 9 (4): 303-314

 

10- Abeer M. Radi ; Naglaa M. Abdel Azeem; EL-Shaymaa EL-Nahass; Fatma Khalil (2014):  Effect of a macrolide antibiotic tulathromycin on  fertility of male albino rats. Veterinary Medical Journal- Giza, Vol. 60, (2), 2014.

11- Abeer M. Radi and Nesreen A. Ibraheem (2015):

Comparison of efficacies of Fosfomycin, Thiamphenicol ,  Nigella sativa oil and its against Escherichia coli infection in chickens.

Assiut Veterinary Medical Journal, Vol. 61, No. (144), January 2015.

 

 

                                                                        : Professional Experience

 

*Teaching Experience

1999\2010:  Teaching Practical Pharmacology to 3rd  year undergraduate students and designing laboratory experiments and exams for students.

 – Faculty of Veterinary Medicine -Beni-suef university

2009 - present: lecturer, Department of Pharmacology, Faculty of veterinary medicine ,Beni -Suef University. Teaching Pharmacology to 3rd  year undergraduate students . Teaching Practical Pharmacology to postgraduate students and designing laboratory experiments and exams for  these students.

1998-present :training of the students on clinical pharmacology in summer training programme, in, Department of Pharmacology, Faculty of veterinary medicine, Beni Suef University, Beni Suef.

*Training programs

 

1-(Faculty & Leadership Development Project; FLDP, Beni Suef           University, Beni suef, Egypt):  

  1. Effective presentation
  2. Strategic Planning
  3. International publishing of research

       4-Use of technology in teaching

        5- University Administration               

              

2- Softwares: Excellent computer knowledge, MS office passed ICDL with excellent scores.

 

Manusrcipts in preparation

 

1) Moawad, Abeer; Hetta, Mona; Hifnawy, Mohamed; Zjawiony, Jordan K;  Ferreira, Daneel ‘ Dihydrobiflavone  Glucosides from Cycas revoluta: a stable atropisomer fo

2) Moawad, Abeer; khan, Shabana; Hetta, Mona;; Hifnawy, Mohamed; Zjawiony, Jordan K;  Ferreira, Daneel: cytotoxic biflavonoids from Cycas

 

 

 

 

 

Conferences and Meetings

1-    Fifth international conference(Towards Safe Food in Egypt),by The Egyptian Society of environmental Toxicology, (2009).

2-     international scientific conference, faculty of Veterinary medicine, Beni-Suef University, (2010 ).

3-    Training course organized by toxicological& Forensic Medicine Department , faculty of veterinary medicine, Cairo university, Egypt. In cooperation with united states Environmental protection Agency(VS-EPA).Risk assessment as a critical tool for everyday's challenges.(2012).

4-    7th international scientific conference, faculty of Veterinary medicine, Suez canal University, (2012).

5-    preparing competitive project for research funding,(2013).

6-    Training course in “nanoscience and nanotechnology”,    

           Faculty of postgraduates for advancen sciences. Beni-Suef   

University, (2013).

7-    The 4th international scientific conference, faculty of Veterinary medicine, Cairo University, (2014).

 

             

 

 


Master Title

Effect ofdrug interaction on ome aspects of sulphadoxine in goats

Master Abstract

SUMMARY ******** This work was carried out to reveal the pharmacokinetic parameters, clearance and creatinine clearance of long acting sulphonamide, sulfadoxine when given alone and in combination with trimethoprim. The effect of both drugs on concentrations of creatinine was also studied. This study was carried out on 12 balady female goats weighing of 20-25 kg and of 18 to 24 months old and proved to be clinically healthy. The goats were divided into four equal groups.The first group was injected sulfadoxine alone intravenously in a dose of 15 mg/kg b. wt. The second group injected sulfadoxine intramuscularly in the same dose of intravenous injection. The third group was injected sulfadoxine and trimethoprim combination intravenously in a dose of (15 mg/kg b. wt.+3 mg/kg b.wt.). The fourth group injected sulfadoxine and trimethoprim combination intramuscularly in the same dose of intravenous injection. Blood, urine samples were collected from goats just before and 5, 10, 15, 30 minutes, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post –injection to study their pharmacokinetic profiles. 1-Single intravenous injection: After intravenous injection of sulfadoxine in a dose of 15 mg/kg b. wt. , the drug was showed a high serum level ( 96.46 ug/ml )5 minutes post-injection, then the concentration was decreased gradually till reached its minimum level ( 1.66 ug/ml) at 120 hours post-injection. While after intravenous injection of sulfadoxine and trimethoprim in a dose of 15 mg/kg b.wt.+3mg/kg b.wt. , the drug was showed a high serum level (93.95 ug/ml) 5 minutes post-injection. Then the concentration was decreased gradually till reached its minimum level (1.24 ug/ml) at 120 hours. The present data revealed that the serum concentration time curves of sulfadoxine were best described by two compartment –open model following a single intravenous injection of 15 mg/kg b. wt. The drugs were distributed with a distribution half –life (t1/2 a) of 2.48hour and 2.31 hour, respectively, and the apparent volume of distribution calculated by area [Vd (area)], extrapolation [Vd(B)] and steady state [Vd(ss)] methods were 384.71±2.19,317.59±3.48 and 368.54±2.99 , respectively for sulfadoxine and 414. 67± 3. 29, 414. 53±000, 420. 29±5. 16 (p<0.01) and 411. 73±3. 48 ml/kg, respectively for sulfadoxine –trimethoprim combination . The drug was distributed in the central compartment with a volume of distribution (Vc)(153.31±2.67 , 156. 85±3.17 ml/kg), respectively. This indicated that trimethoprim increase distribution of sulfadoxine in the body . The drug was eliminated with a half-life of elimination (t1/2 ß) of (23.10 hour and 24.75 hour) for sulfadoxine alone and sulfadoxine –trimethoprim combination, respectively .Body clearance (Cl B)were 0.076±0.004 and 0.073 ±0. 008 l/kg/h, respectively. This indicating that trimethoprim enhance the excretion of sulfadoxine . The concentrations of the drugs in the urine were much higher than its concentration in serum. It were 876.618 and 1328.029ug/ml, respectively at 30 min. post-injection and was reached its maximum level ( 1178.25 and 1505.8 ug/ml )at one hours post-injection and then decreased gradually to reach its lowest concentration(33.5 and 15.278 ug/ml) ,respectively at 120 hours post-injection(p<0.05). The percentage of N4-acetylated derivatives of sulfadoxine was higher in urine than in serum and with sulfadoxine trimethoprim combination than in case of sulfadoxine alone , It reached its maximum levels (60.667%in serum after 72 hours and , 65.216% in urine after 96 hours in goats injected with sulfadoxine and trimethoprim. Whereas it was 50.672%in serum at (48 hr) and 58.33%in urine at (120 hr)in goats injected sulfadoxine alone .This result indicated that the trimethoprim enhance the metabolism of sulfadoxine through acetylation . The rate of sulfadoxine clearance from goat’s blood after a single intravenous injection of both drugs was decreased by time post injection . The creatinine concentrations in serum and urine of goats following a single intravenous injection of 15 mg/kg b.wt. revealed no marked significant altrations. The ratio between sulfadoxine clearance from goats blood to endogenous creatinine clearance was ranged from 0.089-0.260 and 0.173-0.469 following intravenous injection, this value indicated that the glomerular filtration is the main route of excretion of sulfadoxine through goat’s kidney. 2-Single intramuscular injection : Following intramuscular injection of sulfadoxine in a single dose of 15 mg/kg b. wt. , the drug was detected in serum 5 min. post –injection (2. 11ug/ml) .It continued to increase gradually till reached its maximum level ( 26. 18 ug/ml) at 2 hours post-injection. Then it was started to decreased gradually till reached its lowest concentration(0.88 ug/ml) at 120 hours post-injection. In case of and intramuscular injection of sulfadoxine –trimethoprim combination the drug was detected in serum (4.39ug/ml) 5 min. post –injection(p<0.05) and it continued to increase gradually till reached its maximum level (33.52 ug/ml) at 2 hours post-injection (p<0.05), then started to decreased gradually till reached its lowest concentration (0.65 ug/ml )at 96 hours post-injection(p<0.01). The drug was absorbed with a half-life of absorption (t1/2 ab ) of 0.58 hour and 0.42 hours (p<0.05), respectively. This indicating that trimethoprim increase the rate of absorption of sulfadoxine. While its elimination half-life (t1/2 el ) was 23. 89 hours and 17.325 hours (p<0.05) ,respectively. This revealed that trimethoprim enhance the excretion and metabolism of sulfadoxine . The concentration of the drug in urine was much higher than its concentration in serum. It were 235.65 and 325.197ug/ml,respectively at 30 min. , then increased to reach its highest level (1371.483 ug/ml)at one hour post-injection for sulfadoxine alone and reached 763.506ug/ml after 2 hour for sulfadoxine –trimethoprim combination. Then decreased gradually to reach its lowest level (45.132 ug/ml at 120 hours and 15.973 ug/ml at 96 hours post injection(p<0.01) , respectively ) . The percentage of N4-acetylated derivatives of sulfadoxine was higher in urine than in serum and with sulfadoxine trimethoprim combination than in case of sulfadoxine alone , It reached its maximum levels (64.7%in serum(p<0.05) and 72.75% in urine)after 72 hours in goats injected with sulfadoxine and trimethoprim. It was (53.024%in serum ,60.15%in urine )at 72 hr in goats injected sulfadoxine alone .This result indicated that the trimethoprim enhance the metabolism of sulfadoxine through acetylation . The rate of sulfadoxine clearance from goats blood after single intramuscular injection of sulfadoxine and sulfadoxine - trimethoprim combination were decreased by time post- injection. The creatinine concentrations in serum and urine of goats showed no significant alteration ,except at 6 hour there was significant decrease (p<0.05) in case of combination . The creatinine clearance expressing the glomerular filtration rate from goats blood was showed significant increase following intramuscular injection of sulfadoxine - trimethoprim combination (p<0.05). The ratio between sulfadoxine clearance to endogenous creatinine clearance was ranged from 0.285-0.492 and 0.064-0.253, respectively following intramuscular injection of sulfadoxine alone and sulfadoxine - trimethoprim combination. This value indicated that the glomerular filtration is the main route of execration of sulfadoxine through goat’s kidneys.

PHD Title

Some pharmacological studies of some antibiotics in broilers

PHD Abstract

Summary ********* The present work was carried out to reveales some pharmacokinetic aspects of two antibacterials, cephradine and cefquinome in chicken .The bioavailability of cephradine following intramuscular ,subcutanious injection and oral adminstration were estimated . The protien binding percent of both drugs to serum were also estimated. Also tissue distribution and residues of cephradine after repeated oral administration and cefquinome after repeated intramuscular injection for 5 consecutive days were also studied. The in-vitro susceptibility of isolated microorganism from one old day chicks towards the two antibacterials were also investigated. The effect of both antibacterials on serum liver enzymes activity and concentration of uric acid in serum following repeated administration were also studied. The present study was carried out on 114 balady chicken and 50 one day old Fayomy chicks. These birds were obtained from El.Azab project for poultry production in Fayoum Governorate with an avearage body weight from 1.280 to 2.800 kg and aged from 4-12 monthes and proved to be clinically healthy. In the first experiment 72 chickens were classified into six groups each of 12 chickens. The 1st , 2nd ,3rd and 4th groups were injected cephradine in a single dose of 50 mg kg-1b.wt. via oral, intramuscular, subcutaniously and intravenously respectively . Chickens of the 5th and 6th group were injected cefquinome in a single dose of 2 mg kg-1b.wt. intramuscularly and subcutaniously respectively. Blood samples were collected 5, 10, 15 and 30 min. 1, 2, 4, 6, 8, 12 and 24 hours post injection. The concentration of both drugs in serum sample was determined using the microbiological assay method. In the second experiment tissue distribution and residues of cephradine in a dose of 50 mg kg-1 b.wt after repeated oral administration in 24chicken twice daily every 12 hours and cefquinome after repeated intramuscular injectionof 2 mg kg-1b.wt. in 18 chicken once daily for 5 consecutive days were also studied. The chicken were slaughtered in different time and tissue samples were taken from liver, kidney, lungs, spleen, intestine, breast and thigh muscles to determined the concentration of both drugs in serum and tissues. The effect of both drugs on serum liver enzymes and the concentration of uric acid in serum were also studied. The bacterial sensitivity, the minimum inhibitory concentration and minimum bactericidal concentration of both drugs to Escherchia.coli O78, proteus mirabilis and pseudomonas aeroginosa were also investigated. 1-Cephradine 1-Single intravenous injection: After intravenous injection of cephradine in a dose of 50 mg kg-1 b.wt., the drug was showed a high serum level (38.67 ug ml-1) 5 min. post injection, then the concentration decreased gradually till reached its minimum level (0.474 ug ml-1) at 8 h post –injection. The present data revealed that the serum concentration time curves of cephradine were best described by a two compartment –open model. The drug was rapidly distributed with a distribution half-life (t 0.5 a) of 0.120 h and apparent volume of distribution calculated by extrapolation Vd(B), area Vd(area), pseudoequilibrium Vd (ß) and steady state Vd(ss) methods were 6.018, 3.102, 3.336 and 2.187 L/kg respectively. The drug was distributed in the central compartment with a volume of distribution (Vc) 0.836 L/kg., indicating that the drug is highly distributed in extra vascular tissues. The drug was rapidly eliminated with a half-life of elimination (t 0.5 ß) of 1.047 and the body clearance of cephradine (ClB)was 2.35 L/kg/h.The mean residence time(MRT) was 0.991h. 2-Single intramuscular injection: Following intramuscular injection of cephradine in a single dose of 50 mg kg-1 b.wt., the drug was detected in serum 0.083 h post injection (6.048ug ml-1) and it continued to increase gradually thereafter and was reached its maximum level 9.104 at 0.25 h post injection, then started to decrease gradually till reached its lowest concentration 0.34 ug ml-1 at 8 hours. It was rapidly absorbed with a half-life of absorption (t 0.5 ab )of 0.154 h., while its elimination half-life (t 0.5 el) was 0.859 h. .The systemic bioavailability of cephradine following intramuscular injection was 59.386 %. This indicated moderate absorption of the drug from this site of injection. While its in-vitro protein binding percent to serum was 10.03%. These values indicated that the drug is slightly bound to serum proteins. 3-Single subcutaneous injection: Following subcutaneous injection of cephradine in a single dose of 50 mg kg-1b.wt., the drug was detected in serum 0.083 h post injection (6.091ug ml-1) and it continued to increase gradually thereafter and was reached its maximum level 8.018 at 0.25 h post injection, then started to decrease gradually till reached its lowest concentration 0.281 ug ml-1 at 12 hours. It was rapidly absorbed with a half-life of absorption (t 0.5 ab) of 0.364 h., while its elimination half-life (t 0.5 el) was 2.652 h .The systemic bioavailability of cephradine following subcutaneous injection was 84.50 %. This indicated good absorption of the drug from this site of injection. 4-Single oral administration: Following oral administration of cephradine in a single dose of 50 mg kg-1 b.wt., the drug was detected in serum 0.167 h post injection (2.23 ug ml-1) and it continued to increase gradually thereafter and was reached its maximum level 5.33 ug ml-1 at 2 h post injection, then started to decrease gradually till reached its lowest concentration 0.557 ug ml-1 at 8 hours. It was rapidly absorbed with a half-life of absorption (t 0.5 ab) of 0.65 h., while its elimination half-life (t 0.5 el) was 1.74 h .The systemic bioavailability of cephradine following oral administration was 97.97%. This indicated good absorption of the drug from this site of injection. 5-Repeated oral administration : Multiple–dose studies have demonstrated no accumulation of cephradine serum level over 5 days with a 12 hours dosing regimen, where the concentrations of the drug in serum just before and one hour after each dose have been ranged from (0.912 to 1.72.ug ml-1) and ( 7.092 to 10.33ug ml-1)respectively . Cephradine was detected in examined tissues up to 12 h after last dose. Repeated oral administration of cephradine in a dose of 50 mg kg-1 b.wt. twice daily for 5 consecutive days caused no change in serum enzyme activity of SAST and SALT and significant increase in concentration of uric concentration at 72 to 120 hours of administration. 6- In –vitro activity of cephradine against certain pathogen: Escherchia.coli O78 was sensitive to cephradine while proteus mirabilis and pseudomonas aeroginosa were resistant. The minimum inhibitory concentrations of cephradine that prevent the growth of Escherchia.coli O78 , proteus mirabilis and pseudomonas aeroginosa were 32, 128 and more than128 while the minimum bactericidal concentration of the drug that kill them were 64, 128 and more than 128 ug ml-1, respectively. 2-Cefquinome 1-Single intramuscular injection: Following intramuscular injection of cefquinome in a single dose of 2 mg kg-1 b.wt., the drug was detected in serum 0.083 h post injection (6.786 ug ml-1) and it continued to increase gradually thereafter and was reached its maximum level 13.334 at 0.25 h post injection, then started to decrease gradually till reached its lowest concentration 0.525 ug ml-1 at 8 hours. It was rapidly absorbed with a half-life of absorption (t 0.5 ab) of 0.170 h., while its elimination half-life (t 0.5 el) was 3.428 h .While its in-vitro protein binding percent to serum was 6.665%. These values indicated that the drug is slightly bound to serum proteins. 2-Single subcutaneous injection: Following subcutaneous injection of cefquinome in a single dose of 2 mg kg-1 b.wt, the drug was detected in serum 0.083 h post injection (1.545 ug ml-1) and it continued to increase gradually thereafter and was reached its maximum level 5.708 at 15 minutes post injection, then started to decrease gradually till reached its lowest concentration 0.011 ug ml-1 at 24 hours. It was rapidly absorbed with a half-life of absorption (t 0.5 ab) of 0.262 h., while its elimination half-life (t 0.5 el) was 25.023 h. 3-Repeated intramuscular injection: Multiple –dose studies have demonstrated significant accumulation of cefquinome serum level over 5 days with a 24 hours dosing regimen, where the concentrations of the drug in serum just before and on hour after each dose have been ranged from (0.841 to 1.664.ug ml-1) and ( 6.96 to 17.31 ug ml-1)respectively . Cefquinome was detected in examined tissues up to 120 h after last dose . Repeated intramuscular injection of cefquinome in a dose of 2 mg kg-1 b.wt. once daily for 5 consecutive days have caused no change in serum enzyme activity of SAST and SALT and significant increase in concentration of uric concentration at 72 to 120 hours of administration. 4- In –vitro activity of cefquinome against certain pathogen: Escherchia.coli O78, proteus mirabilis and pseudomonas aeroginosa aeroginosa were sensitive to cefquinome. The minimum inhibitory concentrations of cephradine that prevent the growth of Escherchia.coli O78 , proteus mirabilis and pseudomonas aeroginosa were 0.5, 1 and 16 while the minimum bactericidal concentration of the drug that kill them were 1,16 and more than128ug ml-1, respectively. References ***** Al-Moyed, K.A.; Harmal, N.S.; Al-Harasy, A.H. and Al-Shamahy, H.A.(2006): Increasing single and multi-antibiotic resistance in Shigella species isolated from shigellosis patients in Sana'a, Yemen. Saudi Med J.;27(8):1157-1160. Arret, B.; Johnson, D.P. and Kirshbaum, A.(1971): “Outline of details of microbiological assay of antibiotics” Second Revision, J.Pharm.Sci., 60:1690-1694. Arayne, M.S. ; Sultana, N. and Afzal, M. (2007): Cephradine antacids interaction studies Pak J Pharm Sci. ;20 (3):179-184 . Aslam, M.A. ; Ahmed, Z. and Azim, R.(2004): Microbiology and drug sensitivity patterns of chronic suppurative otitis media J Coll Physicians Surg Pak. ;14(8):459-461. Axelrod, J.l. and Kochman, R.S.(1981): Cephradine levels in human aqueous homor. Arch. Ophthalmol. ;99(11):2034-2036. Ayad, A.R.A. (1987): Some pharmacological studies on flumequine in chickens. Ph.D. Thesis, Cairo University , Faculty of Vet. Medicine Badenoch, P. R; Mcdonald, P.J. and Coster, D.J.(1986): Effect of inflammation on antibiotic penetration into the anterior segment of the rat eye. Invest. Opthalmol. Vis.Sci., 27(6): 958-965. Baggot, J.D.(1978): Some aspects of clinical pharmacokinetics in veterinary medicine . J.Vet.Pharmacol. Ther. ,1,5-17 . Baggot, J.D.(1983): Systemic antimicrobial Therapy in large animals, in: Bogan,J.A.:Lees,P.and Yoxall,A.T.(Eds) Pharmacological Basis of Large Animal Medicine ,PP.45-69(Oxford, Blackwell Scientific Publication. Barker, S.A.; Kappel, L.C. and Short, C.R.(1994): Tissue distribution and clearance of the cephalosporin cefquinome in the bovine. Bologna,Italy; Societa Italiana di Buiatria.543-546. Bergogne-Berozin, E.; Morel, C.; Benard, Y.; Berthelot, G. and Kafe, H.(1978): Pharmacokinetic study of beta-lactam antibiotics in bronchial secretions. Scand J. Infect. Dis suppl.;(14):267-272. Bergan, T.(1987): Pharmacokinetic properties of the cephalosporins. Drugs; 34 suppl. 2: 89-104. Bennet, N.;Jean,L.; Brodie; Ernest, J.; Benner and William, M.(1966): Simplified, accurate method for antibiotic assay of clinical speciments. Applied Microbiology,14(2):170-177. Bins, J.W.and Mattie, H.(1988): Saturation of the tubular excretion of beta-lactam antibiotics. Br. J.clin. Pharmacol.;25(1):41-50. Block, .C. Von (1996): Pharmacokinetics of the cephalosporin antibiotic cefquinome in sows at different stages of the erproductive cycle. Inaugural-Dissertation,Tierarztliche Fakultat, Ludwig-Maximilians- Universitat, Munchen,Germany.148 pp. Bottner, A.; Schmid, P. and Humke, R.(1995): Invitro efficacy of cefquinome (INN) and other anti-infective drugs against bovine bacterial isolates from Belgium, France, Germany,The Netherlands,and The united Kingdom. Zentralbl. Veterinarmed B.;42(6): 377-383. Brander, G.C ; Pugh, D.M .; Bywater, R.J. (1982): Cited in veterinary applied pharmacology and therapeutics. 4th ed . the English language Book Society and Boilliere. Tindall, London page 57. Bullen, B.R.; Ramsden, C.H. and Kester, R.C.(1980): Tissue levels of cephradine in ischaemic limbs following a single intravenous injection . Curr. Med. Res.Opin.;6(9):585-588. Bush, M.; Locke, D.; Neal, L.A. and Carpenter, J.W.(1981): Pharmacokinetics of cephalothin and cephalexin in selected avian species. Am.J.Vet.Res. ;42 (6) : 1014-1017. Cain, T.; Jones, G. and Woods, P.(1987): Bone levels of cephradine and cefuroxime after intravenous administration in patients undergoing total hip replacement. Int.Orthop.;11(1):61-63. Calder, W.A. and Brown, E.J.(1983): '' Scaling of osmotic regulation in mammals and birds" Am. J. Physiol. 144: p. 602-606. Carli, S.; Anfossi, P. ; Villa, R.; Castellani, G.; Mengozzi, G. and Montesissa, C.(1999): Absorption kinetics and bioavailability of cephalexin in the dog after oral and intramuscular administration. J.Vet.Pharmacol.Ther.22(5):308-313. Charles, M.G. and George, H.M.(1979) : Pharmacokinetics of cephradine suspention in infants and children. Antimicrobial agents and chemotherapy ;16; (1): 74-76. Chin, N.; Gu, J.; Fang, W. and Neu, H.(1992): Invitro activity of cefquinome, a new cephalosporin,compared with other cephalosporin antibiotics. Diagn.Microbial Infect.Dis.;15(4):331-337. Crosse, R. and Burt, G.D.(1984): Antibiotic concentration in the serum of dogs and cats following a single oral dose of cephalixine. Veterinary Recoed ;115: 106-107. Cruickshank, R.; Dugvuid, J.P.; Marmion, B.P. and Swain, R.H.(1975): “Medical microbiology, the practice of medical microbiology” 12th Ed.,Vol.2,Churchill Livingston, edinburgh and New york. Collee,Cerald. J.; barrie, P. Marmion; Andrew, G. Fraser and Anthory Simmons (1996): Cited in Mackie & Mccartney Practical medical microbiology 4th edition page 151-178. Newyork EclinBurgh London. Committee for veterinary medicinal product (2003): Cefquinome , summary reoprt (3). EMEA,MRL,883/03-final/2003. Committee for veterinary medicinal product (1995): Cefquinome , summary reoprt . EMEA,MRL,005/95. Corti, S. ; Sicher, D.; Regli, W. and Stephan, R.(2003): Current data on antibiotic resistance of the most important bovine mastitis pathogens in Switzerland. Schwiez. Arch Tierheilkd.; 145(12):571-575. Deshpande, L.; Pfaller, M. A. and Jones, R.N. (2000): In vitro activity of ceftiofure tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum –beta lactamase producing strains. Int. J Antimicrob Agents. 15 (4): 271-275. . Dorrestein, G.M.; Van Gogh, H. and Rinzema, G.D.(1984): Pharmacokinetics aspects of penicillin, aminoglycoside and chloramphenicol in birds compared to mammals. A review veterinary Quarterly. 6: pages 216-224. Edwards, P. R. and Ewing, W. H. (1972): Identification of Enterobacteriaceae. Minneapolis, Burgess Publishing Co., Pp. 709. El.Sayed, M.G.; Atef, M.; and El-Komy, A.A.(1994): Disposition kinetics of cephradine in normal and Escherichia coli infected goats. Dtsch Tierarztl Wochenschr ;101(2):59-60. Emke, A.(1994): Respiratory diseases of veal calves: origin, course, and results of cefquinome treatment. Inaugural-Dissertation, Tierarztliche, Hochschule, Hannover,Germany.page 170. Finkelstein, E.; Quintiliani, R.; Lee, R.; Bracci, A. and Nightingale, C.H. (1978): Pharmacokinetics of oral cephalosporins: cephradine , cephalexine. J.Pharm.Sci.;67(10):1447-1450. Fischer, A.(1995): Efficacy of cefquinome against Escherichia coli infection in newborn calves and the development of resistant strains of E.coli. Inaugural-Dissertation, Tierarztliche, Hochschule, Hannover,Germany.page 156.. Funaki, H; Uzuka, Y.; Tanabe, S.; Iwahara, K.; Takaichi, Y.; Kusano, K and Sarashina, T.(2001): Therapeutic efficacy of cefquinome against acute respiratory disease in Holstein steers. Journal of the Japan veterinary medical association,54(6):451-454. Gakuya, F. M; Kyule M.N; Gathura P.B. and Kariuki, S.(2001): Antimicrobial resistance of bacterial organisms isolated from rats. East Afr Med J. ; 78(12):646-649. Garg, S.K.; Chaudhary, R.K. and Srivastava, A.K.(1996): Pharmacokinetics of cephalexin in calves after intravenous and subcutaneous administration. Acta. Vet. Hung.,44(2):195-201. Ganiere, J.P. ; Medaille, C. and Mangion, C. (2005): Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma. J Vet Med B Infect Dis Vet Public Health; 52(1) : 25-31. Gennaro, j.M.; Kathleen, J.R. and Hans, H.G.(1973): Comparison of the chemotherapeutic and pharmacodynamic activities of cephradine, cephalothin and cephaloridine in mice. Antimicrobial Agents and Chemotherapy; 3 ( 2) : 270- 273. Gibbs, H. and Bottner, A.(1994): The use of cefquinome in the treatment of respiratory disease in cattle. Bologna ,Italy;Societa Italiana di-Buiatria.535-538. Gilman, A.G.; Goodman, L.S. and Gilman, A.(1980): Goodman and Gilman 's: The pharmacological Basis of Therapeutic,6th Edn.pp. 21 and 1083.New York, Macmillan publishing Co. Gray, S.J.(1984) : Aeremonas hydrophila in livestock: incidence, biochemical characteristics and antibiotic susceptibility. J.Hyg (Lond).,92(3):365-375. Grove, D.C. and Randall, W.A.(1955): Assay Method of antibiotics. Medical encyclopedia, new york. Guerin-Faublee, V; Carret, G. and Houffschmitt, P.(2003): In vitro activity of 10 antimicrbial agents against bacteria isolated from cows with clinical mastitis. Vet.Rec.;152(15):466-471. Hayashi, Y. and Kojima, T.(1980): Absorptiom and excretion of cefradine in healthy volunteers. Jpn. J. Antibiot.;33(6):655-663. Heinritzi, k. and Hagn, J.(1999) : Studies on the efficacy and safty of the new cephalosporin cefquinome in sows with puerperal septicaemia and toxaemia syndrome. Tierarztliche Praxis.Ausgabe G, Grosstiere/Nutztiere;27(2):114-121. Henry, M.M.; Morris, D.D. ; Lakritz, J. and Aucoin, D.(1992): Pharmacokinetics of cephradine in neonatal foals after single oral dosing. Equine Veterinary Journal 24(3): 242-243. Hoffler, D. and Koeppe, P.(1975): Pharmacokinetics of intravenous cefradine in normal and restricted renal function. Munch Med Wochenschr.;117(27):1169-1174. Hoffstedt, B. and Walder, M. (1981): Influence of serum protein binding and mode of administration on penetration of five cephalosporins into subcutaneous tissue fluid in human. Antimicrobial agents and chemotherapy pp 783-786. Holland , N. L. and Adams, P.M. (2007): Cited in Core Concepts in Pharmacology , second edition ,page 404 . Upper saddle river, New Jersy 07458. Hornish, E.R. and Kotaraski, F.S.(2002) : Cephalosporins in Veterinary Medicine – ceftiofur use in food animals. Current topics in Medicinal chemistry; 2(7):717-731. Jordan, j.; Idoate, I.; Urdaneta, E. and Larralde, J. (1996): Influence of cephalosporins on intestinal enzymatic activity. Rev Esp Fisiol. ;52(1):31-36. Kageyama, N.A.(1971): A direct colorimetric determination of uric acid in serum and urine with uricase-catalase system. Clin.Chim. Acta; 31:421-426. Kiss, I.;Farago, E. and Pinter, J.(1976): Serum and lung tissue levels of cephradine in thoracic surgery. Br.J.Clin.Pharmacol.;3(5):891-895. Klimov, V.S.; Iakovlev, V.P. and Rudzit, E.A.(1975): Comparative study of the circulation of semisynthetic cephalosporins in the blood of rabbits. Antibiotiki.20(7):646-649. Klimova, V.S.(1979): Comparative study of cephalexine and cephradine distribution in the body of rats. Antibiotiki.24(10):764-767. Klimova, V.S. and Iakovlev, V.P.(1979): Comparative study of the interaction of cephalosporins with blood serum proteins and organ homogenates. Antibiotiki ; 24(11): 835-838. Klesel, N. and Seeger, K.(1983): Pharmacokinetic properties of the new cephalosporin antibiotics HR-810 in animals. Infection, 11(60) : 318-321. Kunst, M.W. and Mattie, H.(1978): Probenecid and the antibacterial activity of cephradine in vivo. J.Infect.Dis.;137(6):830-834. Lacey, R.W.; Gillian, L.H; Vickil. l.; Luxton, D.E.A.and Trotter, I.S. (1983): Double-blind study to compare the selection of antibiotic resistance by Amoxycillin or Cephradine in the commensal flora. The lancet ;322( 8349) : 529-532. Lange, I.R.; Rodeck,C . and Cosgrove, R.(1984): The transfer of cephradine across the placenta Br. J.Obestet Gynaecol.;91(6):551-554. Leary, W.P.; Asmal, A.C., Locktt, C.J. and Bima, B.(1975): Apreliminary report on cephradine. S.Afr.Med.J.;49(33);1356-1358. Leigh, D.A.(1989): Determination of serum and bone concentrations of cephradine and cefuroxime by HPLC in patients undergoing hip and knee jont replacement surgery. J. Antimicrob. Chemother.;23(6):877-883. Limbert, M.; Isert, D.; Klesel, N.; Markus, A.; Seeger, K.; Seibert, G; and Schrin, E.(1991): Antibacterial activities in vitro and in vivo and pharmacokinetic of cefquinome (HR111V), anew broad-spectrum cephalosporin. Antimicrob. Agents chemother.;35(1):1419. Locke, D.; Bush, M. and Carpenter, J.W.(1982): Pharmacokinetics and tissue concentration of Jylosin in selected avian species. Am.J.Vet.Res;43(10):1807-1810. Lode, H.; Gebert, S. and Hendrischk, A.(1975): Comparative pharmacokinetics and clinical experience with a new cephalosporin-derivatives: cefazolin. Chemotherapy. ;21(1); 19-32. Longman, L.P; Martin, M.V. and Smalley, J.W.(1987): One and two doses of cephradine in the prophylaxis of experimental streptococcal endocarditis. J.Antimicrob .chemother.;20 (4):557-562. Lorian, V.(1980): Antibiotics in laboratory medicine. 3rd edition ,Wilking Battimore, London, 265-297. Maha,Z.Gaber (2005): Pharmacokinetics of cefquinone and tissue concentration in broilers. Bull.Fec.Pharm Cairo Univ. ; 43( 2) : 201-207. Malmborg, A.S.; Meder, B. and Wersall, J.(1975): Clinical and laboratory evaluation of the effect of cephradine on patients with ear, nose and throat infections. Chemotherapy; 21(5):311-317. Marre, R.; Freiesleben, H.; Beck, H. and Sack, K.(1979): Antimicrobial agents in rats.Serum levels of oral cephalosporins. Arzneimittelforschung.;29(7):990-992. Matharu, S.S.; Ramsden, C.H.; and Kester R.C.(1978): Astudy on tissue concentrations of cephradine achieved in patients with peripheral vascular disease. Curr. Med.Res.Opin.;5(6):427-432. Maryadele, J.O. ; Ann Smith and Patrica, E.H.(2001): The Merck index, An Encyclopedia of chemicals, drugs and Biochemicals. Thirteenth edition, p. 333. Milne,M.H.;Biggs,A.M.;Barrett,D.C.;Young,F.J.;Doherty,S.;Innocet,G.T. and Fitzpatrick, J.L. (2005) : Treatment of persistent intramammary infections with streptococcus uberis in dairy cows. Vet.Rec. ; 157(9):245-250. Minn, F.L.; Sugarman, A.A and Bernfeld, G.E.(1976): Cephradine excretion in humans with PH- alterd urine. J.Clin.Pharmacol. !6(4):171-173. Moffat, A.C. ; Jackson, J.V. : Moss, M.S. ; Widdop, B. and Greenfield, E.S.(1986): Clarke's, Isolation and identification of drugs in pharmaceuticals, body fluids, and post-mortem material. Second edition, London.P.438-439. Morita, E.; Mizuno, N.; Nishikata, M. and Miyake, K.(1990): Comparasion of the pharmacokinetics of five beta-lactam antibiotics between neonatal and adult rats. Dev. Pharmacol.Ther.;14(4): 223-230. Moriwaki, T.;Yasui, H. and Yamamoto, A.(2003): Arecirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference. J.Pharmacokinet. Pharmacodyn.;30:119-144. Morris, P.; Ander, J.; Jose, X. and Jairo, P.D.(1977) : Comparative human oral clinical pharmacology of cefadroxil, cephalexin and cephradine. Antimicrobial agents and chemotherapy; 11(2 ): 331-338. Murphy, S.P.; Erwin, M.E. and Jones, R.N.(1994): Cefquinome(HR111V) in vitro evaluation of abroad- spectrum cephalosporin indicated for infections in animals. Diagn.Microbiol infect. Dis.;20(1):49-55. Navetat ,H.; Griers,P; Lancar, R. and Espinasse, J.(1996): The efficacy of cefquinome in the treatment of infectious enzootic pneumonia in young cattle. Bulletin des G.T.V. (1): 21-25. Nightingale,C.H.; Greene, D.S. and Quintiliani, R.(1975): Pharmacokinetics and clinical use of cephalosporin antibiotics. J. Pharm.Sci. 64: page 1899. Oishi , M.; Nishizuka, K.; Motoyama, M.; Ogawa, T. and Tanaka, M.(1976): Ophthalmic application of intravenous cephradine. Jpn.J.Antibiot.;29(11): 958-962 Orden, J. ; Ruiz-Sanata-Quiteria, J; Garcia, S.; Cid, D. and De La Fuente, R.(1999): In vitro activities of cephalosprins and quinolones against Escherichia coli strains isolated from diarrhiec dairy calves. Antimicrob. Agents chemother.;43(3):510-513. Pengov, A.(2001): Treatment of clinical and subclinical mastitis cases with COBACTAN®. Veterinarske Novice.27(4):145-148. Philipson, A.; Stiernstedt, G. and Ehrnebo, M.(1987): Comparison of the pharmacokinetics of cephradine and cefazoline in pregnant and non- pregnant women. Clin. Pharmacokinet;12 (2):136-144. Quintilani, R.; French, M. and Nightingale, G.M.(1982): First and second generation cephalosporins. Antinicrobial therapy.Med.Clin North Am.;66:183-197. Rassbach, A. and Schimmel, D.(1996): Efficacy of cefqunome against experimental Haemaphilus prasuis infection in primary SPF piglets. Tierarztliche Umschau.51;(7):398-400. Rattie, E.S.; Bernarde, P.D. and Ravin, L.J.(1976): Pharmacokinetic interpretation of cephradine levels in serum after intravenous and extravascular administration in human. Antimicrob.Agent and Chemother.10:283-287. Rose, M.; Schmid, P and Bottner, A.(1996): Application of cefquinome in cattle : concentration vs.time in bronchial secretion and in vitro activity against pasteurella spp. Tierarztliche Umschau.51;(12):760-765. Rose, M. Wissler, R.; Zschiesche, E.; and Thomas, E.(2000): Efficacy and tolerance of a new cephalosporin, cefquinome, formulation for treatment of bacterial respiratory disease of pigs. Tierarztliche praxis. Ausgabe G, Crosstiere/Nutztiere,28(6):331-336. Sader, H.S.; and Jones, N.R.(1993): The fourth- generation cephalosporins: antimicrobial activity and spectrum definitions using cefpirome as an example. Antimicrob.Newslett.9:9. Sacha, P.T. ; Zaremba, M.L. and Jakoniuk, P.(1999): The influence of antibiotics on phagocytic and bacteriocidal activity of rabbit peritoneal macrophages stimulated by filtrates of cultured t-lymphocytes. Med Dosw Mikrobiol. ;51(3-4):399-412. Saif, M. y.; Barnes J.H ; Glisson, j.R.; Fadly, M.A.; McDougald, R.L and Swayne, E.D.(2003): Diseases of poultry. 11th ed. Pages,631,852-853. Sakamoto, H. ;Hirose, T.;Nakamoto,S., Hatano,K.; Shibayama, F.; Kikuchi, H. and Mine, Y.(1988): Pharmacokinetics of FK482, anew orally active cephalosporin, in animals. The Journal of antibiotics Vol.XLI.No.12 page 1896-1905 Sami, I.H.; Kamal, F.A. and Marwan, U.(1977): Cephradine penetration into cerebrospinal fluid and effects of its administration into cerebral ventricles of cats. Antimicrobial agents and chemotherapy.;11(5) : 909-911. Sampimon, O.C.; Vernooij, J.C.; Mevius, D.J. and Sol, J.(2007) : Sensitivty to various antibiotics of coagulase-negative staphylococci isolated from samples of milk from Dutch dairy cattle. Tijdschr Diergeneeskd.;132(6): 200-204. San Martin, B.; Bataglia J.; Hernandez, P.; Quiroz, A. and Canon, H. (1998): Absorption and excretion of cefquinome in coho salmon (oncorhynchus Kisutch) in fresh water at 10 degrees C. Zentralbl.Veterinarmed.A.;45(10);615-623. Schmidt, E. and Schmidt, F.W.(1963): Enzym. Biol. Clin. 3:1. Schmid, P.; Bottner, A.; Humke, R. and Trenti, F.(1994): In vitro testing of bacterial field strains from bovine origin for sensitivity to cefquinome. Italian Association of Buiatrics, Bologna,Italy.2;(1);539-542. Schmidt, H.; Philipp. H; Hamel, U. and Quirke, J.(1998): Treatment of acute respiratory tract disease in cattle with bisolvon in combination with either enrofloxacine, cefquinome, ceftiofure or florfenicol. Tierarztliche praxis. Ausgabe G, Crosstiere/Nutztiere;26(3):127-132. Schimmel, D.(1992): Possibilities for the establishment of pneumonia-free swine herds by immunization and administration of cefquinome. Berl. Munch Tierarztl Wochenscher. 1;105(11):378-380. Schwinghammer, T.L.; Norden, C.W.; and Gill, E.(1990): Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects. J.clin.Pharmacol.; 30(10): 893-899. Schwarz, S.; Alesík, E.; Grobbel, M.; Lübke-Becker, A.; Werckenthin, C.; Wieler, L.H. and Wallmann, J. (2007): Antimicrobial susceptibility of Pasteurella multocida and Bordetella bronchiseptica from dogs and cats as determined in the BfT-GermVet monitoring program 2004-2006. Berl Munch Tierarztl Wochenschr.;120 (9-10):423-430. Sekine, O; Usuda, Y; Higuchi, K.; Watanabe, M.; and Yamasaku, F. (1976): Studies on cephradine for intravenous injection. Jpn.J.Antibiot. 29(11):968-972. Sheldon, I.M.; Bushnell, M.; Montgomery, J. and Rycroft, A.N.(2004): Minimum inhibitory concentrations of some antimicrobial drugs against bacteria causing uterine infections in cattle. Vet. Rec.25;155(13):383-287. Shpigel, N. and Schmid, P.(1997): Treatment of acute bovine mastitis with cefquinome. Tierarztliche praxis.25(3) :200-206. Shpigel, N.; Levin, D.; Winkler, M. ;Saran, A; Ziv, G. and Bottner, A.(1997): Efficacy of cefquinome for treatment of cows with mastitis experimentally induced using Escherichia coli. J.Dairy Sci.;80(2):318-323. Silley, P.; Rudd, A.P.; Symington, W.M. and Tait, A.J.(1988): Pharmacokinetics of cephalexin in dogs and cats after oral, subcutaneous and intramuscular administration. Veterinary Record, 122(91):15-17. Singhvi, S.M.; Heald, A.F. and Schreiber, E.C (1978): Pharmacokinetics of cephalosporin antibiotics:protein binding Considerations. Chemotherapy; 24(3):121-133. Snedecor, G.W.(1969): Statistical methods, 4th ed. The Lowa state univ. Press, Ames. ,Lowa, USA., page 91. Soback, S.; Ziv, G.; Kurtz, B. and Paz, R.(1987): Clinical pharmacokinetics of five oral cephalosporins in calves. Res,vet.Sci.;43(2);166-172. Sultana, N.; Arayne, M.S. and Afzal, M. (2005): Synthesis and antibacterial activity of cephradine metal complexes: part 11 complexes with cobalt, copper, zinc and cadmium. Pak J Pharm Sci. ;18(1):36-42. Takahashi, H.; Kaneko, O. and Fukuda, N.(1976): Administration of cephradine to dermatoses by injection. Jpn. J. Antibiot.;29(11):955-957. Tell, L.; Herrenstien, L.; wetzlich, S.; Needham, M. ; Nappier, J.; Hoffman, G.; Caputo, J. and Craigmill, A.(1998): Pharmacokinetics of ceftifur sodium in exotic and domestic avian species . J. Vet. Pharmacol. Therap. 21, 85-91. Tetzlaff, T. R.; Mc Cracken, G.H. and Thomas, M.L.(1978): Bioacailability of cephalexine in children ,relationship to drug formulation and meals. J.Pediatr. 92:292. Thomas, E.; Martin, G.; Voss, B.; Boettner, A.; Pommier, P.; Loehlein, W. and Hellman, K. (2002): A comparative field study of the efficacy of cefquinome and amoxycillin against acute meningitis of weaned piglets. Pig Journal :50 : 28-41. Thomas, E.; Thomas, V. and Wilhelm, C. (2006): Antibacterial activity of cefquinome against equine bacterial pathogens. Veterinary Microbiology; 115(1-3) : 140-147. Tohamy, M.A.; Ismail, M. and El-Gendy, A.A.M.(2006): Comparative pharmacokinetics of cefquinome in ruminants. J.Egypt. Soc. Pharmacol. Exp. Ther.;27(2): 289-299. Unowsky, J.; Behl, C.R.; Beskid, G.; Sattler, J.; Halpern, J. and Cleeland, R.(1988): Effect of medium chain Glycerides on Enteral and Rectal absorption of B-lactan and aminoglycoside antibiotics. Chemotherapy 34:272-276. Vukovich, R.A.; Brannick,L.J.; Sugerman, A.A.and Neiss, E.S.(1975): Sex differences in the intramuscular absorption and bioavaliability of cephradine . Clin.pharmacol.ther.;18(2):215-220. Wise, R.(1990): The pharmacokinetics of the oral cephalosporins-a review. J. Antimicrob Chemother ; 46 (suppl E) : 13-20. Winter, P.; Hoflechner, A. and Baumgartner, W.(1999): Resistance patterns of ovine mastitis pathogens. Berl. Munch Tierarztl Wochenscher;112(6-7):216-222. Zhang, x.; li, J.; Jiang, H. and Shen, J. (2007): Residue depletion of cefquinome in swine tissues after intramuscular administration. J. Agric. Food Chem.; 55(25):10493-10498. .

All rights reserved ©Abeer Mohamed Radi